----item----
version: 1
id: {63DDB90F-11FE-476D-96C7-734BFEDA5200}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/01/25/BioNotebook Up to 26bn in postJP Morgan stock offerings plus six IPO updates
parent: {9EB2B89B-399D-4AC9-BFEC-41459154D174}
name: BioNotebook Up to 26bn in postJP Morgan stock offerings plus six IPO updates
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: b89234df-0c89-4c30-95aa-ff53d35ff024

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 81

BioNotebook: Up to $2.6bn in post-JP Morgan stock offerings, plus six IPO updates
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 76

BioNotebook Up to 26bn in postJP Morgan stock offerings plus six IPO updates
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 11067

<p>Public biotechnology companies took advantage of excitement for the industry that was generated during the JP Morgan Healthcare Conference from 12 to 15 January in San Francisco by announcing plans to raise up to $2.6bn from stock offerings that will fund acquisitions, clinical trials and regulatory filings.</p><p>The leader of the pack was BioMarin Pharmaceutical, whose offering of 8.5m shares plus 1.3m shares for overallotments raised $911.5m. The large stock sale wasn't unexpected, since the San Rafael, California-based company needed to boost its cash balance following the acquisition of Duchenne muscular dystrophy drug developer Prosensa for $680m up front and up to $160m in milestone payments (scripintelligence.com, <a href="http://www.scripintelligence.com/home/BioMarin-to-pay-840m-for-GSK-castoff-355228" target="_new">24 November 2014</a>).</p><p>The other two-thirds of offerings totaling $20m or more that were announced during the week of 19 to 23 January included biotech companies that have been public for a while and several others that completed initial public offerings in 2014.</p><table><tbody><tr><td><p><b>Company</b></p>&nbsp;</td><td><p><b>Offering terms</b></p>&nbsp;</td></tr><tr><td><p>BioMarin Pharmaceutical;</p><p>San Rafael, California</p>&nbsp;</td><td><p>The developer of biopharmaceuticals for rare and serious diseases sold 8.5m shares for $93.25 each &ndash; plus 1.3m shares for overallotments to meet excess investor demand &ndash; for $911.5m in gross proceeds.</p>&nbsp;</td></tr><tr><td><p>Alnylam Pharmaceuticals;</p><p>Cambridge, Massachusetts</p>&nbsp;</td><td><p>Alnylam is selling 4.7m shares for $95 each and $450m in gross proceeds. With 710,526 shares set aside for overallotments, the company could raise up to $517.5m. The developer of RNA-based therapeutics recently has been trading at a high reached a year ago when it spiked based on deals announced during the 2014 JP Morgan event (scripintelligence.com, <a href="http://www.scripintelligence.com/home/Alnylam-gets-700m-Sanofi-investment-buys-Sirna-from-Merck-349280" target="_new">13 January 2014</a>).</p>&nbsp;</td></tr><tr><td><p>Puma Biotechnology;</p><p>Los Angeles, California</p>&nbsp;</td><td><p>Puma, which has had mixed results for its breast cancer drug neratinib, will gross at least $190m and up to $218.5m from the sale of 1m shares priced at $190 each plus up to 150,000 shares for overallotments (scripintelligence.com, <a href="http://www.scripintelligence.com/researchdevelopment/Puma-sinks-as-neratinib-NDA-delayed-almost-one-year-355376" target="_new">3 December 2014</a>).</p>&nbsp;</td></tr><tr><td><p>Auspex Pharmaceuticals;</p><p>San Diego, California</p>&nbsp;</td><td><p>Auspex will raise $169.5m from the sale of 3m shares priced at $56.50 each, or up to $203.4m with overallotments, to fund its Phase III program and regulatory filings for the Huntington's disease drug SD-809 (scripintelligence.com, <a href="http://www.scripintelligence.com/home/Auspex-rises-on-Phase-III-Huntingtons-data-success-355704" target="_new">17 December 2014</a>).</p>&nbsp;</td></tr><tr><td><p>Zafgen;</p><p>Boston, Massachusetts</p>&nbsp;</td><td><p>Trading at more than twice its June IPO price of $16 per share, Zafgen priced 3.9m shares at $35 each to raise $120m for development of lead weight loss drug candidate beloranib (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Kite-IPO-catches-strong-breeze-plus-Endocyte-Merrimack-Aastrom-Nektar-Horizon-Acorda-Ariad-352463" target="_new">22 June 2014</a>). The company could gross up to $138m, including overallotments.</p>&nbsp;</td></tr><tr><td><p>Radius Health;</p><p>Waltham Massachusetts</p>&nbsp;</td><td><p>Radius priced its IPO at $8 per share in June, but the developer of drugs for osteoporosis and endocrine-mediated diseases has seen its stock more than quadruple since then (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Trevi-Complexa-raise-VC-cash-Deerfield-commits-60m-to-KemPharm-Aradigm-Voyager-deal-news-IPO-updates-352181" target="_new">6 June 2014</a>). The company is offering 4m shares at $36.75 each for gross proceeds of $147m or $169.05m after overallotments.</p>&nbsp;</td></tr><tr><td><p>Arena Pharmaceuticals;</p><p>San Diego, California</p>&nbsp;</td><td><p>Arena's stock jumped to $5.85 earlier in January on positive Phase I results for its S1P1 receptor agonist APD334, but the company's share value dropped sharply to $4.55 as of 23 January after it announced the sale of up to 24m shares at $4.8139 each to gross as much as $115.5m (scripintelligence.com, <a href="http://www.scripintelligence.com/researchdevelopment/Arena-rockets-on-early-data-in-crowded-S1P1-field-355996" target="_new">8 January 2015</a>).</p>&nbsp;</td></tr><tr><td><p>Otonomy;</p><p>San Diego, California</p>&nbsp;</td><td><p>With an offering of 2.55m shares at $29.25 each, the ear drug developer Otonomy is getting close to two times its IPO value of $16 per share in August (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Otonomy-prices-100m-IPO-Vitae-Tokai-plan-to-go-public-GeNO-Drops-IPO-bid-353372" target="_new">13 August 2014</a>). The company's secondary offering will gross at least $74.6m and up to $85.8m with overallotments.</p>&nbsp;</td></tr><tr><td><p>Versartis;</p><p>Menlo Park, California</p>&nbsp;</td><td><p>The growth hormone developer Versartis had one of the highest IPO prices of 2014 at $21 per share, but the company's stock value has fallen since March (scripintelligence.com, <a href="http://www.scripintelligence.com/business/Biotech-IPOs-ride-stock-market-rollercoaster-350821" target="_new">22 March 2014</a>). Versartis priced 4.3m shares at $17.25 each, but with overallotments could gross up to $85.8m in an offering set to close on 27 January.</p>&nbsp;</td></tr><tr><td><p>Verastem;</p><p>Boston, Massachusetts</p>&nbsp;</td><td><p>Verastem, which develops drugs that target cancer stem cells, will gross up to $51.2m from the sale of 7.25m shares plus overallotments. The company's lead drug candidates target the FAK, PI3K/mTOR and Wnt pathways, including the FAK inhibitor VS-4718, which was acquired from Poniard Pharmaceuticals in February (scripintelligence.com, <a href="http://www.scripintelligence.com/home/BioNotebook-Merck-drops-Ariads-ridaforolimus-United-Therapeutics-Infinity-Verastem-updates-Dipexium-Achaogen-IPO-terms-350249" target="_new">26 February 2014</a>).</p>&nbsp;</td></tr><tr><td><p>Vitae Pharmaceuticals;</p><p>Fort Washington; Pennsylvania</p>&nbsp;</td><td><p>Four months after its IPO at $8 per share, Vitae is selling 3m shares at $11.90 each for $35.7m in gross proceeds, or up to $41.1m with the sale of overallotments, to fund clinical trials for its unpartnered drug candidates to treat autoimmune diseases and inflammation (scripintelligence.com, <a href="http://www.scripintelligence.com/researchdevelopment/Post-IPO-Vitae-gets-Phase-I-BACE-hit-advances-new-strategy-354670" target="_new">27 October 2014</a>).</p>&nbsp;</td></tr><tr><td><p>Agile Therapeutics;</p><p>Princeton, New Jersey</p>&nbsp;</td><td><p>Agile expects to complete enrollment for a Phase III clinical trial testing the transdermal contraceptive patch Twirla in the second quarter of 2015. However, the company arranged a private placement of 3.4m shares at $5.85 each for $20m in gross proceeds mainly for general corporate purposes, including potential payments on a prior loan. The shares were sold below Agile's May IPO price of $6 per share, but the company's stock price closed at $7.54 on 23 January (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Big-bets-in-life-science-venture-capital-Chimerix-stock-offering-IPOs-and-dealmaking-abound-351992" target="_new">27 May 2014</a>).</p>&nbsp;</td></tr></tbody></table><p><p><b>Five companies set IPO terms, one withdraws offering</b></p><p>Syndax Pharmaceuticals postponed its $64.5m IPO in June then re-filed for a $74.2m in August and now, as of 22 January, the Waltham, Massachusetts-based cancer drug developer has withdrawn its plan to become a public company (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Three-potential-IPOs-and-a-venture-capital-deal-Dermira-Rhythm-Syndax-OncoPep-353640" target="_new">30 August 2014</a>).</p><p>There still are several biotech companies in the queue, however, and five of them set preliminary terms for IPOs between 20 and 23 January.</p><table><tbody><tr><td><p><b>Company</b></p>&nbsp;</td><td><p><b>IPO terms</b></p>&nbsp;</td></tr><tr><td><p>Spark Therapeutics;</p><p>Philadelphia, Pennsylvania</p>&nbsp;</td><td><p>The gene therapy developer registered an IPO to raise up to $86m with the US Securities and Exchange Commission (SEC) in late December, but the company could gross up to $93.5m from the sale of 5.5m shares priced at $15 to $17 each (scripintelligence.com, <a href="http://www.scripintelligence.com/business/Spark-to-IPO-to-fund-first-US-gene-therapy-approval-355927" target="_new">5 January 2015</a>).</p>&nbsp;</td></tr><tr><td><p>Flex Pharma;</p><p>Boston, Massachusetts</p>&nbsp;</td><td><p>Flex, which is developing therapies for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, registered a $60m IPO with the SEC in late December (scripintelligence.com, <a href="http://www.scripintelligence.com/business/Biotechs-Tracon-Flex-file-for-IPOs-355889" target="_new">30 December 2014</a>). The company could raise up to $64.6m with the sale of 4.6m shares at $12 to $14 each.</p>&nbsp;</td></tr><tr><td><p>Tracon Pharmaceuticals;</p><p>San Diego, California</p>&nbsp;</td><td><p>Tracon originally sought up to $57.5m in an IPO to finance programs in cancer, age-related macular degeneration (AMD) and fibrotic diseases, but the company will raise $50.4m at most under proposed offering terms of 3.6m shares at $12 to $14.</p>&nbsp;</td></tr><tr><td><p>Inotek Pharmaceuticals;</p><p>Lexington, Massachusetts</p>&nbsp;</td><td><p>Glaucoma drug developer Inotek filed for an $86.2m IPO in November (scripintelligence.com, <a href="http://www.scripintelligence.com/business/BioNotebook-Two-deals-two-offerings-seven-IPO-updates-354937" target="_new">8 November 2014</a>). Under its proposed offering terms, the company would gross as much as $69.6m from the sale of 4.6m shares at up to $15 each plus as much as $34.5m from a concurrent offering of convertible senior notes.</p>&nbsp;</td></tr><tr><td><p>Carbylan Therapeutics;</p><p>Palo Alto, California</p>&nbsp;</td><td><p>Carbylan registered an IPO for up to $86.25m with the SEC at the end of December and now the company wants to sell 5.8m shares for $12 to $14 each, which would gross as much as $81.2m for development of Hydros-TA, an intra-articular injection of a low-dose corticosteroid plus a proprietary hyaluronic acid viscosupplement for osteoarthritis of the knee.</p>&nbsp;</td></tr></tbody></table></p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 316

<p>Public biotechnology companies took advantage of excitement for the industry that was generated during the JP Morgan Healthcare Conference from 12 to 15 January in San Francisco by announcing plans to raise up to $2.6bn from stock offerings that will fund acquisitions, clinical trials and regulatory filings.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 76

BioNotebook Up to 26bn in postJP Morgan stock offerings plus six IPO updates
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150125T204730
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150125T204730
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150125T204730
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027620
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 81

BioNotebook: Up to $2.6bn in post-JP Morgan stock offerings, plus six IPO updates
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356259
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042238Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

b89234df-0c89-4c30-95aa-ff53d35ff024
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042239Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
